Product-related advice

• CMDh letter to MAHs of tenofovir disoproxil-containing medicinal products (February 2023, correction: June 2023)

• Q&As on the implementation of the outcome of the Art. 31 referral on angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (December 2021) [Tracked]

Deletion of interaction between broad spectrum antibiotics and combined oral contraceptives (COC)

• Public Assessment Report (March 2015) corrected in March 2016 [Tracked]